Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays.
Diagn Microbiol Infect Dis
; 100(1): 115313, 2021 May.
Article
in English
| MEDLINE | ID: covidwho-1065007
ABSTRACT
OBJECTIVES:
To evaluate the diagnostic performances of four SARS-CoV-2 IgG antibody immunoassays.METHODS:
Following immunoassays were studied Abbott's SARS-CoV-2 IgG assay, Diasorin's Liaison SARS-CoV-2 S2/S2 IgG assay, Euroimmun's Anti-SARS-CoV-2 IgG ELISA, and Roche's Elecsys Anti-SARS-CoV-2 assay. Specificity was retrospectively evaluated with 38 samples from 2019. Sensitivity samples (nâ¯=â¯147) were taken from SARS-CoV-2 real-time PCR-positive patients who developed COVID-19 symptoms ten days earlier.RESULTS:
Mean specificity was 96.6%. Mean sensitivity was 62.7% from ten days after onset of symptoms, 84.4% from 15 days after onset of symptoms, and 87.5% from 20 days after onset of symptoms.CONCLUSIONS:
Specificity was high, while Abbott and Roche were 100% specific. Sensitivity increased over time, with Abbott and Roche having the highest sensitivity at all time points with ≥90% from 20 days after symptoms' onset. These findings may assist in selecting SARS-CoV-2 IgG antibody immunoassays for additional diagnostics, epidemiological research, and vaccine development.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoassay
/
COVID-19 Serological Testing
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
Topics:
Vaccines
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
/
Middle aged
Language:
English
Journal:
Diagn Microbiol Infect Dis
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS